The 5 Top Stocks Cathie Wood Is Buying Now
The 5 Top Stocks Cathie Wood Is Buying Now
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市場新聞，股票建議和交易提示
Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT:ARKK), up more than 15% during the past month. The performance was driven by the release of July's consumer price index (CPI) report. The report revealed that inflation rose by 0% month-over-month (MOM) and by 8.5% year-over-year (YOY). Meanwhile, economists were expecting a YOY increase of 8.7% and a MOM increase of 0.2%.
凱茜伍德的 方舟投資 最近表現良好，她的旗艦交易所交易基金（ETF）的股票 方舟創新ETF （NYSEMKT:ARKK），在過去一個月中上漲了15％以上。7月消費者物價指數（CPI）報告的發佈推動了業績。報告顯示，通貨膨脹率環比（MOM）增長0％，同比（同比）增長8.5％。同時，經濟學家預計同比增長8.7％，環比增長0.2％。
Wood expects further decreases in inflation. The Ark Founder explained, "We will be talking about deflation being a greater risk in the next three to six months. Innovation results in deflation. One of the metrics that have been very telling .. is long term Treasury yields… The bond market is expecting growth to surprise on the low side."
伍德預計通貨膨脹將進一步下降。方舟創始人解釋說：“我們將在未來三到六個月內談論通貨緊縮是更大的風險。創新導致通貨緊縮。其中一個非常有說服力的指標... 是長期美國國債收益率... 債券市場預計低位的增長將出人意料。”
She cited the 10-year Treasury yield's difficulty in staying above 3% as a sign that current rates of inflation are unsustainable. In addition, she believes that falling gas prices are a sign that prices may be easing.
她指出，10年期美國國債收益率難以保持在3％以上，這表明目前的通貨膨脹率是不可持續的。此外，她認爲，天然氣價格下跌表明價格可能正在緩解。
So, what has Ark been buying?
那麼，方舟在買什麼？
5 Cathie Wood Stocks Ark Is Buying Now
5 Cathie Wood 股票 Ark 現在正在買入
Invitae (NYSE:NVTA) has experienced volatile price action since reporting its Q2 earnings on Aug. 9. The following day, shares of NVTA closed higher by a mind-boggling 238%. The genetics testing company posted revenue of $136.6 million, up more than 17% year-over-year. But it still fell short of estimates by just 0.62%. On the other hand, earnings per share came in at loss of 68 cents, beating the estimate for a loss of 74 cents.
邀請 （紐約證券交易所：NVTA）自8月9日公佈第二季度財報以來，價格走勢波動。第二天，NVTA的股價收盤上漲了令人難以置信的238％。這家遺傳學測試公司公佈的收入爲1.366億美元，同比增長17％以上。但它仍然比預期低0.62％。另一方面，每股收益虧損68美分，超過了預期的74美分的虧損。
The company's earnings report did not seem substantial enough to sustain a 238% gain, which had investors speculating that a short squeeze was taking place. As of July 31, 23.1% of the public float was sold short, equating to a monetary volume of $98.38 million. The high short interest was significant enough to drive a short squeeze, paired with investors bidding up the price.
該公司的收益報告似乎還不夠充分，不足以維持238％的漲幅，這讓投資者猜測正在出現空頭擠壓。截至7月31日，23.1％的公衆持股被賣空，相當於9,838萬美元的貨幣交易量。高空頭利息足以推動空頭擠壓，再加上投資者競標價格。
Wood reported purchasing NVTA the day prior to its earnings report. On Aug. 8, ARKK scooped up 186,884 shares, while the ARK Genomic Revolution ETF (BATS:ARKG) picked up 626,059 shares. After the purchases, Invitae is now the 45th largest holding among all ARK ETFs out of 51 total.
伍德在財報發佈前一天報告收購了NVTA。8月8日，ARKK收購了186,884股股票，而 ARK 基因組革命 ETF （蝙蝠：ARKG）收購了626,059股股票。在收購之後，Invitae現在是所有ARK ETF中第45大持股，在總共51只ETF中。
Ark has now purchased shares of Teladoc (NYSE:TDOC) for three consecutive weeks. From Aug. 8 to Aug. 11, 445,481 shares were purchased through four ARK ETFs, including — oddly enough — the ARK Fintech Innovation ETF (NYSEMKT:ARKF). After the purchases, Ark owns a total of 30.6 million shares, making it the largest shareholder by a wide margin.
方舟現在已經購買了以下公司的股票 Teladoc （紐約證券交易所：TDOC）連續三週。從8月8日到8月11日，通過四隻ARK ETF購買了445,481股股票，奇怪的是，其中包括 方舟金融科技創新ETF （NYSEMKT:ARKF）。收購後，Ark共擁有3,060萬股股票，以大幅優勢成爲最大的股東。
Shares of TDOC stock have fallen lower by more than 50% year-to-date, offering a discount opportunity for Ark. On Aug. 11, DA Davidson initiated coverage of the company with a $45 price target. Analyst Robert Simmons characterized the company as a leader in the telehealth space with a variety of offerings. Shares have fallen by more than 85% from the high of $308, although Simmons believes this is an "over-correction." The analyst adds that the current rate of revenue and free cash flow margin growth should provide significant upside.
今年迄今爲止，TDOC股票的股價下跌了50％以上，這爲Ark提供了折扣機會。8月11日 DA Davidson 開始爲該公司提供保險，目標股價爲45美元。分析師羅伯特·西蒙斯（Robert Simmons）將該公司描述爲遠程醫療領域的領導者，提供各種產品。儘管西蒙斯認爲這是 “過度修正”，但股價已從308美元的高點下跌了85％以上。分析師補充說，目前的收入率和自由現金流利潤率的增長應該會提供顯著的上行空間。
3. Roblox (RBLX)
3.Roblox (RBLX)
On Aug. 10, Ark purchased 44,048 shares of Roblox (NYSE:RBLX) through two of its ETFs. This was Ark's first purchase of RBLX since June 9. Ark purchased shares after the metaverse company reported Q2 earnings on Aug. 9, causing shares to plunge lower by more than 10%. Revenue tallied in at $639.9 million, falling short of the analyst estimate of $644.4 million. Earnings per share fell short as well, coming in at a loss of 30 cents versus the expectation for a loss of 21 cents. The EPS figure equated to a net loss of $176.4 million.
8月10日，Ark購買了44,048股股票 Roblox 紐約證券交易所代碼：RBLX）通過其兩隻交易所買賣基金。這是方舟自6月9日以來首次收購RBLX。在這家元宇宙公司於 8 月 9 日公佈第二季度財報後，Ark 購買了股票，導致股價暴跌超過 10%。收入爲6.399億美元，低於分析師估計的6.444億美元。每股收益也低於預期，虧損30美分，而預期的虧損爲21美分。每股收益相當於淨虧損1.764億美元。
Meanwhile, average daily active users (DAUs) clocked in at 52.2 million, coming in below the analyst estimate by about a million users. During Q1, the company reported 54.1 million average DAUs. Despite the misses on several metrics, RBLX stock has since recovered all of the losses attributed to its earnings report, leading investors to believe that the worst may have already been priced in.
同時，平均每日活躍用戶（DAU）爲5,220萬，低於分析師估計的約一百萬用戶。在第一季度，該公司報告的平均DAU爲5,410萬個。儘管多個指標均有失誤，但RBLX股票此後已經收復了收益報告造成的所有損失，這使投資者相信，最壞的情況可能已經定價。
4. Markforged (MKFG)
4.MarkforgedMKFG)
Wood has now purchased shares of Markforged (NYSE:MKFG) for two consecutive weeks, even after the company reported its earnings on Aug. 11. The company operates as a 3D printing and materials provider.
伍德現在已經購買了以下公司的股票 馬克福格 （紐約證券交易所：MKFG）連續兩週，儘管該公司於8月11日公佈了財報。該公司作爲 3D 打印和材料提供商運營。
Revenue rose by 19% YOY to $24.2 million, while net profit rose to $4.1 million, up from a net loss of $11.1 million a year ago. On the other hand, gross margin declined to 53% from 58% a year ago. CEO Shai Terem added:
收入同比增長19％，達到2420萬美元，淨利潤從去年同期的1,110萬美元淨虧損增至410萬美元。另一方面，毛利率從去年同期的58％下降到53％。首席執行官 Shai Terem 補充說：
"We continue to make great strides in executing on our strategy thanks to great efforts from our talented team. We feel very confident in our long-term opportunity to extend our leadership position in distributed manufacturing as our product portfolio grows and evolves."
“得益於我們才華橫溢的團隊的巨大努力，我們在執行戰略方面繼續取得長足的進步。隨着我們產品組合的增長和發展，我們對長期有機會擴大我們在分佈式製造領域的領導地位充滿信心。”
From Aug. 8 to Aug. 12, two ARK ETFs purchased 575,458 shares of MKFG. The largest purchase within that period occurred after earnings on Aug. 12, when 396,856 shares were purchased in a single day. In the month of August, Ark has purchased MKFG on 18 separate occasions.
從8月8日到8月12日，兩隻ARK ETF購買了MKFG的575,458股股票。在此期間最大的一次收購發生在8月12日財報之後，當時一天內購買了396,856股股票。8月，Ark已在18個不同的場合購買了MKFG。
5. Fate Therapeutics (FATE)
5.命運療法 (命運)
From Aug. 11 to Aug. 12, two ARK ETFs purchased 632,542 shares of Fate Therapeutics (NASDAQ:FATE). Interestingly enough, it appears that Wood may have had a quick change of heart, as ARKK sold 307,711 shares on Aug. 8. The recent purchases were the company's first purchases of FATE since Feb. 25.
從8月11日至8月12日，兩隻ARK ETF購買了632,542股股票 命運療法 （納斯達克：命運）。有趣的是，看來伍德可能很快改變了主意，因爲ARKK在8月8日出售了307,711股股票。最近的收購是該公司自2月25日以來首次收購FATE。
Fate operates as a clinical stage biotechnology company that utilizes cellular immunotherapies to treat patients with cancer and immune disorders. During Q2, the company reported revenue of $18.5 million, up 38% YOY. Fate also announced an expanded collaboration with Ono Pharmaceutical (OTCMKTS:OPHLY) to advance its second solid tumor program.
Fate是一家臨床階段的生物技術公司，利用細胞免疫療法來治療癌症和免疫疾病患者。在第二季度，該公司公佈的收入爲1,850萬美元，同比增長38％。Fate 還宣佈擴大與... 的合作 小野製藥 (OTCMKTS:OPHLY）推進其第二個實體瘤項目。
While the company remains unprofitable, it still has seven proprietary cell therapy candidates in its product pipeline. Wood's recent purchases may be a stamp of conviction for the potential of Fate's pipeline.
儘管該公司仍然無利可圖，但其產品線中仍有七種專有細胞療法候選藥物。伍德最近的收購可能是對命運管道潛力的信念。
On the date of publication, Eddie Pan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在發佈之日，埃迪·潘沒有（直接或間接）持有本文提及的證券的任何頭寸。本文中表達的觀點是作者的觀點，受InvestorPlace.com的約束出版指南。
The post The 5 Top Stocks Cathie Wood Is Buying Now appeared first on InvestorPlace.
《凱西·伍德現在正在買入的五隻熱門股票》一文首次出現在 InvestorPlace 上。